Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 5Cyclophosphamide 4Carboplatin 4Filgrastim 3fludarabine 2Thiotepa 2Temozolomide 2Riluzole 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Immunohistochemistry 2Drug Therapy 2Counseling 2Bupropion 2vofatamab 1utomilumab 1trastuzumab deruxtecan 1toripalimab 1tasquinimod 1sodium thiosulfate 1sargramostim 1saracatinib 1poly ICLC 1pertuzumab 1liposomal doxorubicin 1lenvatinib 1ixabepilone 1etoposide phosphate 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × vofatamab × Gynecologic × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡